Chemical-Guided SHAPE Sequencing Reveals RNA Degrader Binding in SARS-CoV-2 5' UTR

Study Background and Research Question

The 5' untranslated region (UTR) of SARS-CoV-2 RNA is a highly structured, evolutionarily conserved segment essential for viral replication, transcription, and translation. These properties make the 5' UTR an attractive target for antiviral strategies that disrupt viral RNA functions. However, the lack of high-resolution tools to map small molecule and chimera binding sites on structured RNA regions has limited rational drug development in this space. The study by Tang et al. addresses this challenge by introducing chemical-guided SHAPE sequencing (cgSHAPE-seq), aiming to illuminate where RNA-degrading chimeras and small molecules bind within the SARS-CoV-2 5' UTR (Tang et al., 2023).

Key Innovation from the Reference Study

Tang and colleagues developed cgSHAPE-seq, a novel sequencing-based approach that couples chemical acylation of RNA at ligand binding sites with high-throughput mapping. The method leverages a tailored acylating probe that covalently modifies the 2'-hydroxyl groups of ribose in proximity to the small molecule-RNA interface. During reverse transcription, these modifications cause read-through mutations at acylated sites—enabling single-nucleotide resolution identification of binding events across structured RNA regions (Tang et al., 2023). This strategy was applied to screen and optimize coumarin derivatives—specifically C30 and C34—that target the SL5 four-way junction in the 5' UTR, ultimately facilitating the rational design of RNA-degrading chimeras for antiviral applications.

Methods and Experimental Design Insights

The researchers began by screening a focused library of coumarin derivatives for binding affinity to the SL5 element using in vitro RNA binding assays. C30 emerged as a lead compound, warranting further investigation. To pinpoint the precise RNA binding site, the team synthesized a cgSHAPE probe combining the coumarin ligand with an acylating chemical group. Key steps of the cgSHAPE-seq protocol include:

• Incubation of the synthetic SL5 RNA with the cgSHAPE probe, allowing selective acylation at the ligand binding interface.
• Reverse transcription of the modified RNA, where acylation-induced lesions cause signature read-through mutations.
• Next-generation sequencing of cDNA products to map mutation sites at single-nucleotide resolution.

This workflow enables accurate localization of small molecule interaction sites within complex RNA secondary structures, a capability not achievable with conventional footprinting or SHAPE analysis (Tang et al., 2023). Following site identification, the authors validated their findings using targeted mutagenesis and in vitro binding experiments. The cgSHAPE chemical scaffold was further adapted to create RNA-degrading chimeras by replacing the acyl group with a ribonuclease L (RNase L) recruiter moiety, enabling functional testing in both cell-free and cellular systems.

Core Findings and Why They Matter

cgSHAPE-seq unambiguously identified a bulged guanosine within the SL5 stem-loop as the primary binding site for C30, a key coumarin derivative. This high-resolution mapping was validated by introducing mutations at the bulged G, which abolished binding and subsequent acylation, confirming the specificity of the interaction (Tang et al., 2023). Extending these insights, the authors created chimeric molecules fusing C30 to RNase L recruiting elements. These RNA-degrading chimeras selectively reduced SARS-CoV-2 5' UTR expression in vitro and in cellular assays. Moreover, optimization of the conjugation site on the coumarin scaffold (notably, the E ring) improved RNA degradation efficacy. The most potent chimera, C64, demonstrated inhibition of live SARS-CoV-2 virus replication in lung epithelial carcinoma cells. These findings are significant because they:

• Demonstrate the feasibility of targeting highly conserved, structured viral RNA with small molecules and chimeras.
• Provide a robust, generalizable method for mapping RNA-ligand interactions at single-nucleotide resolution.
• Enable rational design of next-generation RNA-targeted antivirals by revealing accessible sites for degrader engagement.

Comparison with Existing Internal Articles

Recent advances in RNA integrity preservation and inhibitor development, such as those highlighted in internal articles on murine RNase inhibitors, intersect with the methodologies in Tang et al. For example, Murine RNase Inhibitor (K1046) is featured as a recombinant mouse-derived protein that confers robust RNA degradation prevention in workflows like real-time RT-PCR and cDNA synthesis. These applications require the protection of RNA from ubiquitous pancreatic-type RNases, especially during reverse transcription steps—a critical aspect for protocols like cgSHAPE-seq, where RNA integrity is paramount (internal review). Further, articles such as "Murine RNase Inhibitor: Unraveling RNA Stability Mechanisms" discuss the biochemical rationale for choosing oxidation-resistant, recombinant mouse inhibitors for workflows performed under low-reducing or oxidative conditions. This consideration is directly relevant when adapting cgSHAPE-seq for sensitive or high-throughput applications, where even trace RNase contamination can compromise data integrity.

Protocol Parameters

• RNA binding assay | 1–10 μM ligand | in vitro RNA–small molecule mapping | Defines ligand affinity window for cgSHAPE probe selection | paper
• cgSHAPE probe acylation | 0.1–1 mM probe | RNA footprinting and site mapping | Ensures sufficient acylation for mutation signature detection | paper
• Reverse transcription | Standard RT enzyme with RNase inhibitor (0.5–1 U/μL) | Real-time RT-PCR and cDNA synthesis workflows | Prevents RNA degradation during primer extension, supporting accurate mutation readout | workflow_recommendation
• RNA-degrading chimera assay | 0.1–10 μM chimera | in vitro and cellular RNA degradation | Evaluates functional impact of chimeric degrader on viral RNA | paper

Limitations and Transferability

While cgSHAPE-seq provides unprecedented resolution for mapping small molecule binding sites on structured RNA, several limitations remain. First, the method requires chemical synthesis of custom probes, which may limit broad accessibility. Second, although the SL5 structure is highly conserved among SARS-CoV-2 lineages, structural context in full viral genomes or infected cells may influence ligand accessibility and efficacy. Furthermore, while the study demonstrated chimera activity in cell lines, translation to primary cells or in vivo models requires further validation (Tang et al., 2023). Transferability to other structured viral RNAs or non-viral targets will depend on the ability to design suitable chemical probes and the stability of RNA secondary structures in relevant biological contexts. Nevertheless, cgSHAPE-seq represents a promising platform for accelerating structure-guided RNA-targeted drug discovery.

Why this cross-domain matters, maturity, and limitations

The intersection of RNA chemical biology (cgSHAPE-seq), antiviral drug discovery, and advanced RNA protection strategies illustrates a maturing landscape in therapeutic RNA targeting. The ability to precisely map small molecule and degrader binding sites on viral RNA informs not only the development of direct-acting antivirals but also enhances best practices in RNA handling—critical for both research and translational applications. However, further work is needed to standardize and simplify cgSHAPE-seq workflows for broader adoption and to systematically evaluate the generalizability of mapped sites across viral strains and biological systems (Tang et al., 2023).

Research Support Resources

Researchers aiming to replicate cgSHAPE-seq, optimize real-time RT-PCR, or prevent RNA degradation during cDNA synthesis and in vitro transcription can benefit from robust RNase A inhibitors. Murine RNase Inhibitor (SKU K1046, APExBIO) is a recombinant protein that specifically and stably inhibits pancreatic-type RNases, supporting protocols that demand high RNA integrity even under low reducing conditions (source: product_spec). Its oxidation-resistant design aligns well with sensitive RNA-centric workflows described in cgSHAPE-seq and related studies.